- JNJ-31020028
-
- $43.00 / 5mg
-
2026-02-02
- CAS:1094873-14-9
- Min. Order:
- Purity: 99.65%
- Supply Ability: 10g
- JNJ 31020028
-
- $1.00 / 1KG
-
2019-09-06
- CAS: 1094873-14-9
- Min. Order: 1KG
- Purity: 95%~99%
- Supply Ability: per week 100kg
|
| | JNJ 31020028 Basic information |
| Product Name: | JNJ 31020028 | | Synonyms: | JNJ 31020028;N-(4-(4-(2-(diethylamino)-2-oxo-1-phenylethyl)piperazin-1-yl)-3-fluorophenyl)-2-(pyridin-3-yl)benzamide;N,N-Diethyl-4-[2-fluoro-4-[[2-(3-pyridinyl)benzoyl]amino]phenyl]-alpha-phenyl-1-piperazineacetamide;4-[1-(BENZENESULFONYL)-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRROLO[2,3-B]PYRIDIN-2-YL]BENZALDEHYDE;JNJ31020028, >98%;JNJ-31020028?, >98%;CS-1745;JNJ-31020028;JNJ 31020028 | | CAS: | 1094873-14-9 | | MF: | C34H36FN5O2 | | MW: | 565.68 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1094873-14-9.mol |  |
| | JNJ 31020028 Chemical Properties |
| Boiling point | 677.5±55.0 °C(Predicted) | | density | 1.228±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 21.5 mg/mL (38.01 mM; Need ultrasonic and warming) | | form | Powder | | pka | 12.14±0.70(Predicted) | | color | Light yellow to yellow |
| | JNJ 31020028 Usage And Synthesis |
| Description | JNJ-31020028 is a brain-permeable selective antagonist of the neuropeptide Y (NPY) receptor Y2 (IC50s = 8.51, 6.03, and 6.17 nM for human, rat, and mouse receptors, respectively) with over 100-fold selectivity for Y2 over Y1, Y4, and Y5 receptors. JNJ-31020028 inhibits calcium release induced by peptide YY in a functional assay in KAN-TS cells (pKB = 8.04) and blocks NPY(13-36)-induced decreases in twitch contraction amplitude in isolated rat vas deferens (IC50 = 7.94 nM). Administration of JNJ-31020028 to rats during abstinence (20 mg/kg per day, i.p.) reverses nicotine-induced social anxiety-like behavior and increases hippocampal Y2 receptor mRNA levels. It reverses withdrawal-induced anxiety-like behavior in rats in the elevated plus maze following a single bolus dose of alcohol when administered at a dose of 15 mg/kg. In an olfactory bulbectomized rat model of depression, chronic JNJ-31020028 treatment (10 nmol per day, i.c.v.) decreases immobility time in the forced swim test but has no effect in control animals. | | Uses | JNJ-31020028 is a selective and brain penetrant antagonist of neuropeptide Y Y2 receptor with pIC50 values of 8.07 and 8.22 for human and rat Y2 receptor, respectively. JNJ-31020028 can be used for the research of nervous disease[1]. | | in vivo | JNJ-31020028 (0-20 mg/kg; s.c. once) affects the level of plasma corticosterone and refeeding result in stressed animals[1]. | Animal Model: | Stressed and nonstressed male Sprague-Dawley rats[1] | | Dosage: | 0, 3, 10 and 20 mg/kg | | Administration: | Subcutaneous injection; 0-20 mg/kg once | | Result: | Significantly decreased plasma corticosterone levels in stressed animals, but not significantly affected plasma corticosterone levels in nonstressed animals. Attenuated effects of stress on refeeding. |
| | References | [1] Shoblock JR, et al. In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y DOI:10.1007/s00213-009-1726-x |
| | JNJ 31020028 Preparation Products And Raw materials |
|